Navigation Links
Novel microfluidic HIV test is quick and cheap
Date:7/16/2010

UC Davis biomedical engineer Prof. Alexander Revzin has developed a "lab on a chip" device for HIV testing. Revzin's microfluidic device uses antibodies to "capture" white blood cells called T cells that are affected by HIV. In addition to physically binding these cells the test detects the types and levels of inflammatory proteins (cytokines) released by the cells.

Revzin's team collaborated with UCLA electrical engineer Prof. Aydogan Ozcan to integrate an antibody microarray with a lensfree holographic imaging device that takes only seconds to count the number of captured cells and amount of secreted cytokine molecules. The test returns results six to twelve times faster than traditional approaches and tests six parameters simultaneously, based on a small blood sample. The Revzin team published the results of their experiments in the May 2010 issue of Analytical Chemistry.

With further refinements, the test will have wide potential use for multi-parametric blood analysis performed at the point of care in the developing world and resource-poor areas. Its affordability will also make it an attractive option in wealthier areas. Revzin has filed for a patent and is looking for ways to bring his test into clinical use.

"In addition to HIV testing and monitoring, this device will be useful for blood transfusions, where the safety of blood is frequently in question," Revzin says.

The most accurate and effective way to diagnose and monitor HIV infection involves counting two types of T-cells, calculating the ratio between the two types of T-cells, and measuring cytokines. Scientists do this using a method called flow cytometry that requires an expensive machine and several highly trained specialists. Healthcare workers and AIDS activists in the developing world have called for less expensive, more easily performed tests.

"While the point of care field focuses on detection of single parameter (e.g. CD4 counts), we believe that the simplicity of the test need not compromise information content. So, we set out to develop a test that could be simple and inexpensive but would provide several parameters based on a single injection of a small blood volume," explains Revzin.

The HIV test addresses two distinct challenges of blood analysis: 1) capturing the desired cell type from blood, which contains multiple cell types, and 2) connecting the desired blood cell type with secreted cytokines. The test consists of polymer film imprinted with an array of miniature spots. Each spot contains antibodies specific to the two kinds of T-cells (CD4 and CD8) and three types of cytokines printed in the same array. When the blood flowed across the antibody spots, T cells stopped and stuck on the spots.

Each T-cell type was captured next to antibody spots specific for the cytokines they might produce. When antibodies activated the cells, spots adjacent to the cells captured the cytokines they secreted. This connected a specific T-cell subset to its secreted cytokines. The visible color intensity of antibody spots revealed differences in cytokine production by T-cells. Prof. Ozcan's lensfree on-chip imaging allowed the scientists to rapidly image and count T-cell arrays without the use of any lenses or mechanical scanning. Analysis of CD4 and CD8 T-cell numbers, the CD4/CD8 ratio and three secreted cytokines took only seconds.

In the future, Prof. Revzin envisions adding microarrays to the test that can detect proteins from the HIV and hepatitis C viruses.


'/>"/>

Contact: Holly Ober
hjober@ucdavis.edu
University of California - Davis - Health System
Source:Eurekalert  

Related biology news :

1. NIH-supported study finds novel pathway may open doors for new blood pressure treatments
2. Novel protein essential for successful pregnancy
3. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
4. Novel processing technologies developed for extending use of oats in gluten-free diet
5. Novel strategy for generating induced pluripotent stem cells for clinical use is safe and efficient
6. International research team discovers novel genes influencing kidney disease risk
7. Researchers use novel nanoparticle vaccine to cure type 1 diabetes in mice
8. Pitt-led international study identifies human enzyme that breaks down potentially toxic nanomaterials, opens door to novel drug delivery
9. OptiNoses novel intranasal sumatriptan product highly effective in treating migraines
10. UMMS researchers uncover novel genetic pathway responsible for triggering vascular growth
11. Novel Parkinsons treatment strategy involves cell transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel microfluidic HIV test is quick and cheap
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology: